Anthos, Novartis

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the ...
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...
At Novartis India, the focus on gender equality and the promotion of women in leadership roles is not just a corporate initiative—it's a commitment ingrained in the organisation's culture. Speaking to ...
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...